Drug Combinations Reduce HIV Transmission Risk

Chicago  In a study that supports the widely used drugs to help control the AIDS pandemic, researchers said on Wednesday that HIV patients who take the drug combination has a much smaller chance to infect their partners. Using a combination of drugs to reduce the possibility of transmission of 92 percent, the researchers report in the journal Lancet. They said the findings meant a combination of drugs known as highly active antiretroviral therapy, or HAART, may be useful as a means of prevention and treatment. “These results … until now strong evidence that HAART can reduce HIV transmission risk,” said Dr. Connie Celum, a professor of medicine and global health University of Washington, who worked on this study.

The team analyzed 3400 pairs from seven African countries. In each pair, one positive among immunodeficiency virus, or HIV, which causes AIDS. The team tested the couple because they are easier to trace. All couples were given counseling about HIV prevention methods, and some were given HIV drugs.

During the study, 349 HIV-infected people began taking the drug combination. Of the 103 partners of patients taking the drug, only one was infected with the virus. “Data observation strongly supports the hypothesis that antiretroviral therapy substantially reduces the risk of HIV infection and transmission,” Dr. Deborah Donnell from the Institute of Vaccines and Infectious Diseases at the Fred Hutchinson of Cancer Research Center in Seattle.

Donnell said, the drugs cut the concentration of HIV in the blood to extremely low levels, which can make people not easy to transmit. In people who take the drug, the virus was suppressed to very low levels in almost 70 percent of cases. A randomized trial is now underway to see whether the effect
immortal.

“While awaiting those results, our research indicates that antiretroviral therapy may have significant public health benefits as well as clinical benefits for individuals who were treated,” Donnell said in a statement. He said the findings offer strong arguments to begin early treatment for HIV. But although at a slower partner handled, drugs provide benefit.

AIDS virus infects 33 million people globally and has killed 25 million since the pandemic began in the 1980s. There is no cure and a vaccine but the drugs keep patients ‘healthy’. Without treatment, the viral damage to the immune system, leaving patients vulnerable to infections and cancer.

More than 20 drugs now on the market and can be combined in various ways to control the virus, although it usually mutates and ultimately the patient must switch to different ways to keep under control. Manufacturers of drugs that includes GlaxoSmithKline, Pfizer, Gilead, Bristol-Myers and Abbott Laboratories, according to Reuters.

Donor money for health care in developing countries could be spent more effectively if it were channeled through a single global fund

Donor money for health care in developing countries could be spent more effectively if it were channeled through a single global fund, experts said Friday.A steady flow of funds is essential for health sector improvements, Gorik Ooms from Belgium’s Institute of Tropical Medicine said.

Research by Ooms and other experts published in The Lancet medical journal Friday said the amount and regularity of international aid was often unpredictable, making it hard for governments to plan ahead.Another study, by Harvard Medical School and the University of Washington, found that in some recipient countries, mainly in sub-Saharan Africa, foreign health aid was partly replacing — not supplementing — domestic health budgets.

In such countries, for every $1 given in aid, governments move between 43 cents and $1.14 of their own health funds to other sectors, such as education or sanitation.”Governments compensate for exceptional international generosity to the health sector by reallocating government funding to other sectors,” Ooms wrote in The Lancet.He said governments also compensated for the unreliability of aid by spreading it over several years.One way to make health aid more stable would be to disburse it via a common pool, similar to the Global Fund To Fight AIDS, Tuberculosis and Malaria set up in 2002.

“If a young institution such as the Global Fund already stands out as delivering stable and predictable financing, it shows the potential advantage of pooling international aid,” Ooms wrote.In a news briefing, he said countries with high dependency on aid usually received pledges from donors for two to four years ahead.”When we in our own countries consider reforming health care, we make estimates for 20, 30, 40 years ahead: how much money will we have? what will happen with the population? what will be the health needs?,” he said.

Another issue is donors’ delivery on their promises.Madalo Nyambose, assistant director at the debt and aid division in Malawi’s Finance Ministry, said aid money was often disbursed later than promised, forcing recipient governments to borrow from financial markets and incur interest payments.

Ooms said a new global health fund could borrow ideas from the Global Fund, which pools donors’ money and allocates it in consultation with the countries in need and independent experts. Its board includes representatives of donors and recipient governments, non-governmental organizations (NGOs), businesses and affected communities.The U.S. researchers examined data on 113 developing countries from 1995 to 2006.(Reuters)